Interventional Cardiology

We’re committed to advancing cardiology through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.

Delivering Meaningful Innovation

A Pioneering Alternative to Blood Thinners. The WATCHMAN™ Left Atrial Appendage Closure Device is the only FDA-approved alternative to warfarin for reducing stroke risk in patients with non-valvular atrial fibrillation. WATCHMAN is covered by Medicare and Medicaid Services for patients meeting certain coverage criteria. The launch of WATCHMAN further solidifies our position in the structural heart market.

Healing with Confidence. The SYNERGY™ System is the only FDA-approved stent with a bioabsorbable polymer coating, which promotes healing and frees patients from long-term polymer exposure. SYNERGY continues to improve patients’ lives while boosting Interventional Cardiology performance.

Designed for Complete Control. The LOTUS Edge™ Valve System* is a next-generation TAVR valve designed to offer complete control throughout the procedure. The exclusive controlled mechanical expansion is designed to provide predictable, precise valve placement and results the first time.

*Lotus is an investigational device and not available for sale in the U.S.

Sources

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update. A report from the American Heart Association. Circulation 2014; 129: e28-e292.

2. Colilla et al. Am J Cardiology, 2013; 112:1142-1147.

3. Holmes, DR et al. Seminars in Neurology, 2010; 30:528–536.